Tag: HFpEF

Novo Nordisk has discontinued the Phase 3 HERMES and ATHENA trials of ziltivekimab after the earlier ZEUS failure raised doubts that IL-6 suppression would translate into cardiovascular benefit. ARTEMIS remains the key ongoing Phase 3 test of the program.